Geopolitical conflict in Iran threatens global medicine supply chains: systemic risks and structural vulnerabilities exposed
Original framing: “As the Iran war disrupts supplies, will it affect access to medicines?” — The Conversation - Global
The original framing omits the historical context of U.S. sanctions on Iran since 1979, which have systematically degraded Iran’s pharmaceutical and medical infrastructure, forcing reliance on gray-market imports. It also ignores the role of Indian and Chinese generic manufacturers as critical buffers in global supply chains, and the disproportionate impact on Global South nations already struggling with medicine shortages. Indigenous and traditional medicine systems in the region, which have historically supplemented pharmaceutical access, are erased entirely.
Medium structural omission detected in mainstream coverage.
The narrative is produced by Western-centric think tanks and media outlets (e.g., The Conversation) that frame geopolitical conflicts through a security lens, serving the interests of pharmaceutical corporations and Western governments by normalizing sanctions as 'necessary' tools of foreign policy. This framing obscures the complicity of these actors in destabilizing regions through economic warfare, while deflecting attention from their role in dismantling public health systems via austerity and privatization. The focus on 'short-term protections' legitimizes reactive policies that benefit elites while ignoring structural reforms needed to decentralize production.
The current crisis is the latest iteration of a 45-year pattern where U.S. sanctions on Iran have disrupted medical supply chains, dating back to the 1979 hostage crisis and intensifying under Trump’s 'maximum pressure' campaign. Similar disruptions occurred during the Iran-Iraq War (1980–1988), when sanctions forced Iran to develop indigenous pharmaceutical production, only for these capacities to be dismantled in the 1990s under neoliberal structural adjustment programs. Historical parallels include the 1990s Yugoslav Wars, where sanctions led to medicine shortages and the rise of black-market pharmaceutical networks, demonstrating how economic warfare consistently destabilizes public health.
The Iran war’s disruption of medicine supplies is not an isolated incident but a symptom of a global health system engineered for fragility, where 40 years of sanctions, corporate consolidation, and neoliberal trade policies have prioritized profit over people.